{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:59Z","timestamp":1792794539668,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["TI-2321805"],"award-info":[{"award-number":["TI-2321805"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R43CA254493-01"],"award-info":[{"award-number":["1R43CA254493-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovate Alabama"},{"DOI":"10.13039\/100016419","name":"Breast Cancer Research Foundation of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"DOI":"10.1038\/s44386-026-00074-1","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:01Z","timestamp":1788458401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Closing the recapitulation gap in obesity-conditioned TNBC drug development"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-1695","authenticated-orcid":false,"given":"Karim I.","family":"Budhwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Stringer-Reasor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Sorace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea L.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"74_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"74_CR2","unstructured":"IQVIA Institute. Global Oncology Trends 2025. 65 (IQVIA Institute for Human Data Science, 2025)."},{"key":"74_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-021-00301-6","volume":"21","author":"A Honkala","year":"2022","unstructured":"Honkala, A., Malhotra, S. V., Kummar, S. & Junttila, M. R. Harnessing the predictive power of preclinical models for oncology drug development. Nat. Rev. Drug Discov. 21, 99\u2013114 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"74_CR4","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.cell.2023.02.026","volume":"186","author":"L Wakefield","year":"2023","unstructured":"Wakefield, L., Agarwal, S. & Tanner, K. Preclinical models for drug discovery for metastatic disease. Cell 186, 1792\u20131813 (2023).","journal-title":"Cell"},{"key":"74_CR5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.tibtech.2022.04.003","volume":"40","author":"KI Budhwani","year":"2022","unstructured":"Budhwani, K. I., Patel, Z. H., Guenter, R. E. & Charania, A. A. A hitchhiker\u2019s guide to cancer models. Trends Biotechnol. 40, 1361\u20131373 (2022).","journal-title":"Trends Biotechnol."},{"key":"74_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & De Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346\u2013354 (2013).","journal-title":"Nature"},{"key":"74_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107, M. & Damjanovi\u0107, A. Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014How we can rise to the challenge. Cells 8, 957 (2019).","journal-title":"Cells"},{"key":"74_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9, 176\u2013198 (2019).","journal-title":"Cancer Discov."},{"key":"74_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","volume":"65","author":"C Belli","year":"2018","unstructured":"Belli, C. et al. Targeting the microenvironment in solid tumors. Cancer Treat. Rev. 65, 22\u201332 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"74_CR11","doi-asserted-by":"crossref","unstructured":"Nia, H. T., Munn, L. L. & Jain, R. K. Physical traits of cancer. Science 370, eaaz0868 (2020).","DOI":"10.1126\/science.aaz0868"},{"key":"74_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos, T., Munn, L. L. & Jain, R. K. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer 4, 292\u2013319 (2018).","journal-title":"Trends Cancer"},{"key":"74_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash, J. & Shaked, Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 14, 1375\u20131388 (2024).","journal-title":"Cancer Discov."},{"key":"74_CR14","doi-asserted-by":"crossref","unstructured":"Harborg, S. et al. Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis. npj Breast Cancer 7, 119 (2021).","DOI":"10.1038\/s41523-021-00325-6"},{"key":"74_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41574-018-0126-x","volume":"15","author":"DF Quail","year":"2019","unstructured":"Quail, D. F. & Dannenberg, A. J. The obese adipose tissue microenvironment in cancer development and progression. Nat. Rev. Endocrinol. 15, 139\u2013154 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"74_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10555-022-10031-9","volume":"41","author":"LE Hillers-Ziemer","year":"2022","unstructured":"Hillers-Ziemer, L. E., Kuziel, G., Williams, A. E., Moore, B. N. & Arendt, L. M. Breast cancer microenvironment and obesity: challenges for therapy. Cancer Metastasis Rev. 41, 627\u2013647 (2022).","journal-title":"Cancer Metastasis Rev."},{"key":"74_CR17","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan, D. S. M. et al. Body mass index and survival in women with breast cancer\u2014systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 25, 1901\u20131914 (2014).","journal-title":"Ann. Oncol."},{"key":"74_CR18","doi-asserted-by":"publisher","unstructured":"Sun, H. et al. Triple\u2011negative breast cancer and its association with obesity. Mol. Clin. Oncol. 935\u2013942. https:\/\/doi.org\/10.3892\/mco.2017.1429 (2017).","DOI":"10.3892\/mco.2017.1429"},{"key":"74_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canlet.2021.03.024","volume":"509","author":"K Kaul","year":"2021","unstructured":"Kaul, K., Misri, S., Ramaswamy, B. & Ganju, R. K. Contribution of the tumor and obese microenvironment to triple negative breast cancer. Cancer Lett. 509, 115\u2013120 (2021).","journal-title":"Cancer Lett."},{"key":"74_CR20","doi-asserted-by":"crossref","unstructured":"Chen, H. et al. The relationship between central obesity and risk of breast cancer: a dose\u2013response meta-analysis of 7,989,315 women. Front. Nutr. 10, 1236393 (2023).","DOI":"10.3389\/fnut.2023.1236393"},{"key":"74_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01940","volume":"10","author":"A Naik","year":"2019","unstructured":"Naik, A., Monjazeb, A. M. & Decock, J. The obesity paradox in cancer, tumor immunology, and immunotherapy: potential therapeutic implications in triple negative breast cancer. Front. Immunol. 10, 1\u201312 (2019).","journal-title":"Front. Immunol."},{"key":"74_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2024.100162","volume":"24","author":"EE Bamberg","year":"2024","unstructured":"Bamberg, E. E. et al. Obesity-driven changes in breast tissue exhibit a pro-angiogenic extracellular matrix signature. Matrix Biol. Plus 24, 100162 (2024).","journal-title":"Matrix Biol. Plus"},{"key":"74_CR23","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1038\/s41388-025-03521-x","volume":"44","author":"ML Hawes","year":"2025","unstructured":"Hawes, M. L. et al. Oncogenic effects of ECM remodeling in obesity and breast cancer. Oncogene 44, 3409\u20133421 (2025).","journal-title":"Oncogene"},{"key":"74_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/1541-7786.MCR-17-0508","volume":"16","author":"LW Bowers","year":"2018","unstructured":"Bowers, L. W. et al. Leptin signaling mediates obesity-associated CSC enrichment and EMT in preclinical TNBC models. Mol. Cancer Res. 16, 869\u2013879 (2018).","journal-title":"Mol. Cancer Res."},{"key":"74_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-019-1153-9","volume":"21","author":"RA Sabol","year":"2019","unstructured":"Sabol, R. A. et al. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models. Breast Cancer Res. 21, 1\u201314 (2019).","journal-title":"Breast Cancer Res."},{"key":"74_CR26","doi-asserted-by":"crossref","unstructured":"Papakonstantinou, E., Piperigkou, Z., Karamanos, N. K. & Zolota, V. Altered adipokine expression in tumor microenvironment promotes development of triple negative breast cancer. Cancers 14, 4139 (2022).","DOI":"10.3390\/cancers14174139"},{"key":"74_CR27","doi-asserted-by":"publisher","first-page":"155620","DOI":"10.1016\/j.prp.2024.155620","volume":"263","author":"S Kumar","year":"2024","unstructured":"Kumar, S. & Chaudhri, S. Recent update on IGF-1\/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer. Pathol. Res. Pract. 263, 155620 (2024).","journal-title":"Pathol. Res. Pract."},{"key":"74_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-016-0163-7","volume":"5","author":"S Balaban","year":"2017","unstructured":"Balaban, S. et al. Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab. 5, 1\u201314 (2017).","journal-title":"Cancer Metab."},{"key":"74_CR29","doi-asserted-by":"crossref","unstructured":"Wang, Y. Y. et al. Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells. JCI Insight 2, e87489 (2017).","DOI":"10.1172\/jci.insight.87489"},{"key":"74_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1158\/0008-5472.CAN-23-0505","volume":"83","author":"C Bouche","year":"2023","unstructured":"Bouche, C. & Quail, D. F. Fueling the tumor microenvironment with cancer-associated adipocytes. Cancer Res. 83, 1170\u20131172 (2023).","journal-title":"Cancer Res."},{"key":"74_CR31","first-page":"1","volume":"2014","author":"A Naba","year":"2014","unstructured":"Naba, A., Clauser, K. R., Lamar, J. M., Carr, S. A. & Hynes, R. O. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 2014, 1\u201323 (2014).","journal-title":"eLife"},{"key":"74_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.ajpath.2010.11.076","volume":"178","author":"MW Conklin","year":"2011","unstructured":"Conklin, M. W. et al. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 178, 1221\u20131232 (2011).","journal-title":"Am. J. Pathol."},{"key":"74_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-61034-3","volume":"16","author":"Q Zhu","year":"2025","unstructured":"Zhu, Q. et al. Integrative spatial omics reveals distinct tumor-promoting multicellular niches and immunosuppressive mechanisms in Black American and White American patients with TNBC. Nat. Commun. 16, 1\u201323 (2025).","journal-title":"Nat. Commun."},{"key":"74_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/cpt.1211","volume":"106","author":"IH Bartelink","year":"2019","unstructured":"Bartelink, I. H. et al. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin. Pharmacol. Ther. 106, 148\u2013163 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"74_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.critrevonc.2019.06.008","volume":"141","author":"M Jove","year":"2019","unstructured":"Jove, M., Spencer, J., Clench, M., Loadman, P. M. & Twelves, C. Precision pharmacology: mass spectrometry imaging and pharmacokinetic drug resistance. Crit. Rev. Oncol. Hematol. 141, 153\u2013162 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"74_CR36","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1158\/0008-5472.CAN-18-2293","volume":"79","author":"DD Truong","year":"2019","unstructured":"Truong, D. D. et al. A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells. Cancer Res. 79, 3139\u20133151 (2019).","journal-title":"Cancer Res."},{"key":"74_CR37","doi-asserted-by":"publisher","first-page":"2303088","DOI":"10.1002\/advs.202303088","volume":"11","author":"D Choi","year":"2024","unstructured":"Choi, D. et al. Microfluidic organoid cultures derived from pancreatic cancer biopsies for personalized testing of chemotherapy and immunotherapy. Adv. Sci. 11, 2303088 (2024).","journal-title":"Adv. Sci."},{"key":"74_CR38","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1111\/febs.16778","volume":"290","author":"K Kyriakopoulou","year":"2023","unstructured":"Kyriakopoulou, K., Koutsakis, C., Piperigkou, Z. & Karamanos, N. K. Recreating the extracellular matrix: novel 3D cell culture platforms in cancer research. FEBS J. 290, 5238\u20135247 (2023).","journal-title":"FEBS J."},{"key":"74_CR39","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.3390\/cancers17182958","volume":"17","author":"DD De Nobrega","year":"2025","unstructured":"De Nobrega, D. D. et al. Evaluation of a novel pan-RAS inhibitor in 3D bioprinted tumor models. Cancers 17, 2958 (2025).","journal-title":"Cancers"},{"key":"74_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont, S. et al. Role of YAP\/TAZ in mechanotransduction. Nature 474, 179\u2013184 (2011).","journal-title":"Nature"},{"key":"74_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00263-3","volume":"7","author":"S Timbrell","year":"2021","unstructured":"Timbrell, S. et al. FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity. npj Breast Cancer 7, 1\u201313 (2021).","journal-title":"npj Breast Cancer"},{"key":"74_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891\u2013906 (2009).","journal-title":"Cell"},{"key":"74_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"74_CR44","doi-asserted-by":"publisher","first-page":"553716","DOI":"10.1200\/JCO.2026.44.16_suppl.e13133","volume":"44","author":"LA Boykin","year":"2026","unstructured":"Boykin, L. A. et al. Characterizing spatial tumor architecture and ECM recapitulation using an EO771 syngeneic TNBC model. J. Clin. Oncol. 44, 553716 (2026).","journal-title":"J. Clin. Oncol."},{"key":"74_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01418-1","volume":"20","author":"A Le Naour","year":"2020","unstructured":"Le Naour, A. et al. EO771, the first luminal B mammary cancer cell line from C57BL\/6 mice. Cancer Cell Int. 20, 1\u201313 (2020).","journal-title":"Cancer Cell Int."},{"key":"74_CR46","first-page":"1039","volume":"66","author":"SE Lynch","year":"2025","unstructured":"Lynch, S. E. et al. Granzyme B PET imaging predicts response to immunotherapy in a diet-induced obesity model of breast cancer. J. Nucl. Med. 66, 1039\u20131045 (2025).","journal-title":"J. Nucl. Med."},{"key":"74_CR47","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived Xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"74_CR48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin, J. et al. Humanized mouse models for immuno-oncology research. Nat. Rev. Clin. Oncol. 20, 192\u2013206 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"74_CR49","doi-asserted-by":"crossref","unstructured":"Aouad, P. et al. Preclinical models of breast cancer metastasis: strengths, limitations, and clinical relevance. npj Breast Cancer 12, 96 (2026).","DOI":"10.1038\/s41523-026-00928-x"},{"key":"74_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/SLA.0000000000004200","volume":"272","author":"TT Sepp\u00e4l\u00e4","year":"2020","unstructured":"Sepp\u00e4l\u00e4, T. T. et al. Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer. Ann. Surg. 272, 427\u2013435 (2020).","journal-title":"Ann. Surg."},{"key":"74_CR51","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1158\/1078-0432.CCR-21-4165","volume":"28","author":"TT Seppala","year":"2022","unstructured":"Seppala, T. T. et al. Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response. Clin. Cancer Res. 28, 3296\u20133307 (2022).","journal-title":"Clin. Cancer Res."},{"key":"74_CR52","doi-asserted-by":"publisher","unstructured":"Boykin, L. A. et al. Protocol for spatial characterization of ECM collagen-GAG in colorectal cancer tumor microenvironment. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.06.25.661355 (2025).","DOI":"10.1101\/2025.06.25.661355"},{"key":"74_CR53","unstructured":"U.S. Food and Drug Administration. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs (2025)."},{"key":"74_CR54","unstructured":"National Institutes of Health. Catalyzing The Development and Use of Novel Alternative Methods. (National Institutes of Health, 2024)."},{"key":"74_CR55","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/aor.14503","volume":"47","author":"JJ Han","year":"2023","unstructured":"Han, J. J. FDA Modernization Act 2.0 allows for alternatives to animal testing. Artif. Organs 47, 449\u2013450 (2023).","journal-title":"Artif. Organs"}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00074-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:00:06Z","timestamp":1788458406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-026-00074-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1038\/s44386-026-00074-1","relation":{},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.I.B. is co-inventor on issued patents generally relating to in vitro, ex vivo, and cancer supermodel technologies discussed conceptually in this Perspective, including US 10,114,010 B1; US 10,969,383 B1; US 11,097,274 B2; US 11,833,514 B2; US 11,965,876 B1; and US 12,518,880 B1. Rights to these technologies are held by CerFlux. K.I.B., C.L.C., and D.J.B. are CEO-Scientist, Director of Research, and Advisor of CerFlux, respectively. K.I.B. and E.M.S.R. serve on various boards. E.M.S.R. consults with and has received institutional funding from pharmaceutical companies including Seagen, Novartis, Merck, Pfizer, Corcept Therapeutics, AstraZeneca, Lilly, Gilead, Tesaro, and GSK. K.I.B. is a member of the Editorial Board of\n                      npj Drug Discovery\n                      and was not involved in the journal\u2019s review of, or decisions related to, this manuscript. The other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"39"}}